Back

Lipid-lowering therapy is associated with lower mortality in heart failure patients: Insights from Swedish national registries data from 2006 to 2022

31 August 2025 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Prognosis and heart failure Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Anton Berg

Institute of Medicine - Sahlgrenska Academy - University of Gothenburg, Gothenburg (Sweden)

6 More presentations in this session

Presentation thumbnail
Cardiorenal outcomes and all-cause mortality in patients with comorbid heart failure and chronic kidney disease across three countries (The CaRe Study)
Associate Professor G. Savarese (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Short-term exposure to low and high temperatures and mortality in heart failure patients: a nationwide study in Sweden
Professor S. Agewall (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of the INTERMACS class and advanced HF according to 4 HFA-ESC 2018 criteria: Insights From the HELP-HF Registry
Doctor M. De Carli (Rozzano, IT)
Abstract Slides Video
Presentation thumbnail
Right ventricular-pulmonary artery coupling in acute heart failure: prognostic significance and implications for intensive care management
Miss A. Caputo (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Risk of adverse events in takotsubo syndrome compared to heart failure: observations from a global federated network
Doctor E. Tartaglia (Modena, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Prognosis and heart failure

The Event

Event poster

ESC Congress 2025

31 August 2025 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Association of lipid-lowering drug treatment with all-cause and cardiovascular mortality among people aged 75 years and above without cardiovascular disease: evidence from a cohort study
thumbnail
Congress Presentation
Lipid risk profile in elderly patients with AHF and long-term follow-up
thumbnail
Congress Presentation
Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: Real-life data from the Swedish Heart Failure Registry 2013-2020

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources